[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lipoprotein-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lipoprotein-disorder":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100618147","phase-2-phase-2-study-of-kylo-11-in-ascvd-patients-with-elevated-lpa-100618147",false,"NCT07327840","Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)","A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of Kylo-11 in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)","Inclusion Criteria:\n\n* Age 18 to 80 years\n* Clinical diagnosis of atherosclerotic cardiovascular disease with elevated Lp(a)\n* Other inclusion criteria applied per protocol.\n\nExclusion Criteria:\n\n* Have moderate to severe heart failure (New York Heart Association \\[NYHA\\] Functional Classification III or IV during Screening) or last known left ventricular ejection fraction \\\u003C30%\n* Have uncontrolled hypertension (systolic blood pressure \\[SBP\\] ≥160 mmHg or diastolic blood pressure \\[DBP\\] ≥100 mmHg)\n* Have uncontrolled cardiac arrhythmia defined as recurrent and highly symptomatic ventricular tachycardia, atrial fibrillation with rapid ventricular response, or supraventricular tachycardia that are not controlled by medications, in the past 3 months prior to randomization\n* Have had any malignancy within 5 years prior to randomization (except for non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in situ, or stage 1 prostate carcinoma that has been successfully treated)\n* Other exclusion criteria applied per protocol.","ALL","18 Years","80 Years",{"count":20,"type":21},204,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a phase 2, double-blind, randomized, placebo-controlled, multi-center, dose-finding study to evaluate the efficacy and safety of Kylo-11 administered subcutaneously compared to placebo in participants with ASCVD and elevated Lp(a).",[27],"Lipoprotein Disorder","RECRUITING","2026-06-23",{"date":31,"type":32},"2026-06-25","ACTUAL",{"date":34,"type":32},"2025-10-29",{"date":36,"type":21},"2028-08-31",{"name":38,"class":39},"Kylonova (Xiamen) Biopharma co., LTD.","INDUSTRY",59,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":5},"100617921","the-effect-of-lipoprotein-a-on-arterial-stiffness-endothelial-function-and-myocardial-deformation-100617921","NCT07324902","The Effect of Lipoprotein (a) on Arterial Stiffness, Endothelial Function and Myocardial Deformation","The Effect of Lipoprotein (a) on Arterial Stiffness, Endothelial Function and Left Atrial and Left Ventricular Deformation - An Observational Study.","Lpa_endo","Inclusion Criteria:\n\n* Adults participants 18-75 years old\n* Willing to sign the informed consent and paerticipate in the study\n\nExclusion Criteria:\n\n* History of autoimmune\u002Fautoinflammatory disease,\n* Severe valvular heart disease,\n* severe chronic kidney disease(eGFR\\\u003C60 ml\u002Fmin\u002F1.73 m2),\n* Active Pregnancy\n* Severe hepatic impairment.",true,"75 Years",{"count":52,"type":21},300,"OBSERVATIONAL","1. Introduction Lipoprotein(a), or Lp(a), is a type of lipoprotein that is structurally similar to LDL (low-density lipoprotein) but carries an additional protein called apolipoprotein (a).\n2. Purpose of the Study\n\n   The primary purpose of this study is to investigate the effect of Lp(a) levels on arterial stiffness, endothelial function, and left atrial (LA) and left ventricular (LV) deformation over a 12-month follow-up period.\n\n   Secondarily, the study will investigate:\n   * a) The incidence of major adverse cardiovascular events (MACE), including cardiovascular death, acute myocardial infarction, and acute stroke.\n   * b) The correlation between MACE incidence and parameters of arterial stiffness, endothelial function, and LA\u002FLV deformation.\n   * c) The levels of oxidative load markers.\n3. Materials and Methods This observational study will include adults aged 18-75 years (regardless of gender) who visit the outpatient clinics of the 2nd University Cardiology Clinic at \"Attikon\" General Hospital. All participants will sign a consent form. A full medical history, clinical examination, and blood collection will be performed to determine levels of Total Cholesterol, LDL-C, HDL-C, triglycerides, and Lp(a) at each visit..\n\nParticipants will be divided into three groups:\n\n* Group A: Lp(a) ≥50 mg\u002FdL with Total Cholesterol\\\u003C200 mg\u002Fdl\n* Group B : Lp(a) \\\u003C50 mg\u002FdL. with Total Cholesterol\\>200 mg\u002Fdl\n* Group C (Control): Lp(a) \\\u003C50 mg\u002FdL. with Total Cholesterol\\\u003C200 mg\u002Fdl At each group n ≥ 100 participants are anticipated.\n\nMeasurements at baseline, at 6 and at 12 months:\n\n* Arterial Stiffness: Determination of carotid-femoral pulse wave velocity (cf-PWV) using the Complior SP device and 24-hour pulse wave analysis with the Mobil-O-Graph device.\n* Endothelial Function: Measurement of the endothelial glycocalyx thickness of sublingual capillaries using a Sidestream Dark Field (SDF) camera (GlycoCheck). This is expressed through the perfused boundary region (PBR) index.\n* Cardiac Deformation: Use of two-dimensional strain (speckle tracking) to calculate the Global Longitudinal Strain (GLS) of the LV and LA strain.\n* Oxidative Load: Determination of malondialdehyde (MDA) and protein carbonyls (PCs) levels as markers of oxidative stress using spectrophotometric kits.\n\nStatistical Analysis: Comparisons regarding the changes in these markers over 6 and 12 months will be conducted between the three groups.",[27,56,57],"Arterial Stiffness","Endothelial Dysfunction",[59,60,61,62,63],"lipoprotein a","artrial stiffness","endothelial glycocalyx","myocardial deformation","oxidative stress","2026-03-10",{"date":66,"type":32},"2026-03-11",{"date":68,"type":32},"2024-09-25",{"date":70,"type":21},"2027-08-17",{"name":72,"class":73},"University of Athens","OTHER"]